Company profile
Regencell Bioscience Holdings Limited (RGC)
About Regencell Bioscience Holdings Limited
from the company's filings and listing- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Chief executive
- Yat-Gai Au
- Employees
- 10
- Listed since
- Jul 16, 2021
- Market value
- $2.9B
- Price to earnings
- -
- Earnings per share
- -$0.01
- Dividend yield
- -
Earnings
6 reported quarters · next on Oct 31, 2022| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Jun 15, 2026 | -$0.01 | n/a | n/a | n/a | EPS n/aRevenue n/a |
| Nov 18, 2025 | -$0.00 | n/a | n/a | n/a | EPS n/aRevenue n/a |
| Jun 26, 2025 | -$0.14 | n/a | n/a | n/a | EPS n/aRevenue n/a |
| Oct 25, 2024 | -$0.00 | n/a | n/a | n/a | EPS n/aRevenue n/a |
| Jan 26, 2024 | $0.00 | n/a | n/a | n/a | EPS n/aRevenue n/a |
| Oct 27, 2023 | -$0.01 | n/a | n/a | n/a | EPS n/aRevenue n/a |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way; basis unverified means we could not classify the reported figure. A flag reads n/a only when a number is missing. An estimate is a forecast made by analysts, not a company target.
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Change | Of company |
|---|---|---|---|---|
| Geode Capital Management, LLC | $2.6M | 422,011 | +1.6% | 0.09% |
| Alyeska Investment Group, L.P. | $2.5M | 416,261 | +100.0% | 0.08% |
| Legal & General Group PLC | $779K | 128,000 | +1192.5% | 0.03% |
| Jane Street Group, LLC | $599K | 98,348 | +100.0% | 0.02% |
| Citadel Advisors LLC | $459K | 75,300 | +474.8% | 0.02% |
| Jane Street Group, LLC | $396K | 65,100 | +132.5% | 0.01% |
| XTX Topco Ltd | $366K | 60,061 | +100.0% | 0.01% |
| Susquehanna International Group, LLP | $290K | 47,700 | +41.1% | 0.01% |
| Amundi | $287K | 47,159 | +448.7% | 0.01% |
| UBS Group AG | $263K | 43,208 | +80.9% | 0.01% |
| Quadrature Capital Ltd | $254K | 41,750 | +100.0% | 0.01% |
| Citadel Advisors LLC | $202K | 33,200 | +56.6% | 0.01% |
A 13F reports long US equity positions 45 days after the quarter ends, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory.
Questions
Why are no insider or congress trades shown for RGC?
This page lists no open-market insider filing and no congressional disclosure in Regencell Bioscience Holdings Limited. A congressional disclosure names a company by its ticker symbol alone, and a symbol can be reassigned after its previous holder leaves the market. 6 disclosures filed under RGC are dated before this company began trading under it, and are not shown here. The filing tables appear as filings are published.
How to read a Form 4
A DECISION THE INSIDER MADE
COMPENSATION PLUMBING
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Sep 10, 2026.
Related companies
also in HealthcareGetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.
